{"protocolSection": {"identificationModule": {"nctId": "NCT03423342", "orgStudyIdInfo": {"id": "STUDY00001830"}, "secondaryIdInfos": [{"id": "1R21HL126209-01", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/1R21HL126209-01"}], "organization": {"fullName": "University of Washington", "class": "OTHER"}, "briefTitle": "Nicotinamide Riboside in Systolic Heart Failure", "officialTitle": "Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure"}, "statusModule": {"statusVerifiedDate": "2022-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-05-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-04-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-06-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-04-11", "studyFirstSubmitQcDate": "2018-01-30", "studyFirstPostDateStruct": {"date": "2018-02-06", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-06-11", "resultsFirstSubmitQcDate": "2022-10-26", "resultsFirstPostDateStruct": {"date": "2022-11-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-10-26", "lastUpdatePostDateStruct": {"date": "2022-11-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Kevin O'Brien", "investigatorTitle": "Professor, Medicine/Cardiology", "investigatorAffiliation": "University of Washington"}, "leadSponsor": {"name": "University of Washington", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide (NAD), or the NADH/NAD ratio. In mouse models of HF, we have found that normalization of the NADH/NAD, through supplementation with NAD+ precursors, is associated with improvement in cardiac function. This Study will randomize participants with systolic HF (ejection fraction \u226440%) to treatment with the NAD precursor, nicotinamide riboside (NR) or matching placebo, uptitrated to a final oral dose of 1000mg twice daily, to determine the safety and tolerability of NR in participants with systolic HF.", "detailedDescription": "Aim 1: Determine the safety and tolerability of NR in patients with clinically stable, systolic heart failure (LVEF \\<40%). To accomplish this Aim:\n\nA) a total of 30 participants with clinically stable, systolic heart failure (LVEF \\<40%) will undergo 2:1 randomization to NR 250mg PO twice daily or matching placebo B) NR (or matching placebo), will be increased weekly by 250mg/dose (500mg/day) to a final dose of 1000mg PO twice daily. Clinic visits with labs bi-weekly during dose escalation will assess HF symptoms and monitor labs \\[B-type natriuretic peptide (BNP), complete blood count (CBC), glycosylated hemoglobin, alanine aminotransferase (ALT), creatine kinase (CK), insulin/glucose, uric acid, electrolytes, blood urea nitrogen (BUN) and creatinine (Cr).\n\nC) to ensure intermediate-term safety and tolerability, participants will continue on their maximum tolerated dose (of NR or placebo) through Study Week 12\n\nAim 2: Determine whether, at the doses employed, NR and NAD are detectable in whole blood.\n\nAim 3 (Exploratory): Assess the range of potential effect sizes of NR on HF surrogate endpoints using:\n\nA) Six-minute walk tests (6MWTs) at each visit (including Screening) to assess functional capacity B) Echocardiography at Baseline and Week 12 to assess LV systolic function (by real-time, 3D echocardiography) and diastolic function (by integrated Doppler and tissue Doppler imaging)"}, "conditionsModule": {"conditions": ["Heart Failure, Systolic"], "keywords": ["nicotinamide riboside", "Nicotinamide-Adenine Dinucleotide"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "2:1 randomization to nicotinamide riboside vs. matching placebo", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "TRIPLE", "maskingDescription": "Randomization and dispensing of matching placebo will be performed by Investigational Drug Services at the University of Washington", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Nicotinamide Riboside", "type": "EXPERIMENTAL", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.", "interventionNames": ["Dietary Supplement: nicotinamide riboside"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DIETARY_SUPPLEMENT", "name": "nicotinamide riboside", "description": "nicotinamide riboside capsule", "armGroupLabels": ["Nicotinamide Riboside"], "otherNames": ["Niagen"]}, {"type": "DRUG", "name": "Placebo", "description": "matching placebo capsule", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)", "description": "Adverse Events", "timeFrame": "up to 12 weeks"}], "secondaryOutcomes": [{"measure": "On-Trial Change in Whole Blood NAD+ Levels", "description": "Between-group comparison of On-Trial Change in Whole Blood NAD+ Levels", "timeFrame": "Week 12-Week 0"}, {"measure": "Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment", "description": "Incidence of On-Trial Abnormal Laboratory Values and/or Adverse Events that Are Related to Treatment", "timeFrame": "16 weeks"}, {"measure": "Effect of NR on Change in Mitochondrial Function (Maximal Oxygen Consumption Rate)", "description": "Mitochondrial Respiration in Isolated Peripheral Blood Mononuclear Cells by the Seahorse (R) Assay", "timeFrame": "Week 12 - Week 0"}], "otherOutcomes": [{"measure": "Exploratory Endpoint: Effect of NR on Functional Capacity", "description": "Change in Six Minute Walk Distance", "timeFrame": "Week 12 - Week 0"}, {"measure": "Exploratory Endpoint: Effect of NR on Change in Left Ventricular Systolic Function", "description": "Change in Left Ventricular Ejection Fraction by 3D-Transthoracic Echocardiography", "timeFrame": "Week 12 - Week 0"}, {"measure": "Exploratory Endpoint: Effect of NR on Left Ventricular Diastolic Function", "description": "Tissue Doppler Imaging, e'", "timeFrame": "Week 12 - Week 0"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Men and women aged 18 and older with systolic heart failure \\[left ventricular ejection fraction (LVEF) by standard 2D echocardiography or radionuclide ventriculography of \u226440%\\] deemed, in the clinical opinion of their treating cardiologist to be non-ischemic or ischemic in origin.\n* Clinically stable (no cardiac procedures or hospitalizations for hospitalizations for cardiac causes, including HF, ischemia or arrhythmia) within the previous 3 months\n* Ability to undergo study procedures, including scheduled visits, blood draws and six-minute walk test (6MWT)\n* Willingness/ability to provide informed consent\n\nExclusion Criteria:\n\n* Heart failure with preserved ejection fraction (LVEF greater than 40%)\n* Heart failure due, in the opinion of their treating cardiologist, to etiologies other than non-ischemic or ischemic. Examples of exclusionary heart failure etiologies include primary valvular disease, or infiltrative or inflammatory cardiomyopathies.\n* Cardiac surgery, percutaneous coronary intervention (PCI) or cardiac device implantation within the previous 3 months\n* Hospitalizations for cardiovascular causes, including heart failure, chest pain, stroke, transient ischemic attack or arrhythmias within the previous 3 months\n* Inability to perform Study visits or procedures (e.g., physical inability to perform 6MWT)\n* Unwillingness/inability to provide informed consent\n* ALT greater than 3 times the upper limit of normal, hepatic insufficiency or active liver disease\n* Recent history of acute gout\n* Chronic renal insufficiency with creatinine \u22652.5mg/dL\n* Pregnant (or likely to become pregnant) women\n* Significant co-morbidity likely to cause death in the 6 month follow-up period\n* Significant active history of substance abuse within the previous 5 years\n* Current participation in another long-term clinical trial\n* History of intolerance to NR precursor compounds, including niacin or nicotinamide", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Kevin D O'Brien, MD", "affiliation": "University of Washington", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Washington", "city": "Seattle", "state": "Washington", "zip": "98195", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "A de-identified, public access database will be made available two years after publication of the primary study results. Data files will be delivered in electronic format, providing meta-data that completely describes the tables, variables and coding. Both the raw data and the primary analysis files will be included. Primary analysis files are a compilation of key variables used to generate the statistical results, to help assure that investigators reach consistent conclusions when analyzing the data to published results. Data, documentation and all other materials will be delivered to NHLBI, as well as a document that fully describes the data, steps taken to de-identify the data, and quality control procedures. A document summarizing data tables and other files that are being delivered and describing the data manipulations applied to the data to assure data anonymity, including an annotated clinical study report providing the database variable names.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR", "ANALYTIC_CODE"], "timeFrame": "2 years following Study completion"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule"}, {"id": "FG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule"}, {"id": "BG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "30"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58", "lowerLimit": "37", "upperLimit": "81"}, {"groupId": "BG001", "value": "60", "lowerLimit": "39", "upperLimit": "76"}, {"groupId": "BG002", "value": "59", "lowerLimit": "37", "upperLimit": "81"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "23"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "28"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "27"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "30"}]}]}]}, {"title": "Sitting Blood Pressure Systolic", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "106", "lowerLimit": "65", "upperLimit": "139"}, {"groupId": "BG001", "value": "106", "lowerLimit": "96", "upperLimit": "122"}, {"groupId": "BG002", "value": "106", "lowerLimit": "65", "upperLimit": "139"}]}]}]}, {"title": "Sitting Blood Pressure Diastolic", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "67", "lowerLimit": "45", "upperLimit": "104"}, {"groupId": "BG001", "value": "64", "lowerLimit": "58", "upperLimit": "68"}, {"groupId": "BG002", "value": "66", "lowerLimit": "45", "upperLimit": "104"}]}]}]}, {"title": "Heart rate", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "beats/min", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "67", "lowerLimit": "42", "upperLimit": "84"}, {"groupId": "BG001", "value": "66", "lowerLimit": "55", "upperLimit": "80"}, {"groupId": "BG002", "value": "67", "lowerLimit": "45", "upperLimit": "84"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "95", "lowerLimit": "62", "upperLimit": "141"}, {"groupId": "BG001", "value": "96", "lowerLimit": "56", "upperLimit": "115"}, {"groupId": "BG002", "value": "95", "lowerLimit": "56", "upperLimit": "141"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "170", "lowerLimit": "104", "upperLimit": "196"}, {"groupId": "BG001", "value": "176", "lowerLimit": "161", "upperLimit": "188"}, {"groupId": "BG002", "value": "172", "lowerLimit": "104", "upperLimit": "196"}]}]}]}, {"title": "Smoking: Never", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Alcohol: Never", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Non-ischemic heart failure", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "19"}]}]}]}, {"title": "Left ventricular (LV) ejection fraction [LV stroke volume (SV)/LV end-diastolic volume (LVEDV)]", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "percentage of ejection fraction", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28", "lowerLimit": "11", "upperLimit": "40"}, {"groupId": "BG001", "value": "28", "lowerLimit": "14", "upperLimit": "39"}, {"groupId": "BG002", "value": "28", "lowerLimit": "11", "upperLimit": "40"}]}]}]}, {"title": "Previous myocardial infarction", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "11"}]}]}]}, {"title": "Previous coronary artery bypass surgery", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Previous percutaneous coronary intervention", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "History of hypertension", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "9"}]}]}]}, {"title": "History of dyslipidemia", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "17"}]}]}]}, {"title": "History of atherosclerotic disease (coronary, peripheral or carotid)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "History of atrial fibrillation", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "History of atrial flutter", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "History of diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "9"}]}]}]}, {"title": "Liver disease", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Emphysema", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Serum potassium", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "mEq/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.2", "lowerLimit": "3.4", "upperLimit": "4.8"}, {"groupId": "BG001", "value": "4.3", "lowerLimit": "3.9", "upperLimit": "4.7"}, {"groupId": "BG002", "value": "4.2", "lowerLimit": "3.4", "upperLimit": "4.8"}]}]}]}, {"title": "Serum glucose", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "131.7", "lowerLimit": "73.0", "upperLimit": "364.0"}, {"groupId": "BG001", "value": "114.1", "lowerLimit": "72.0", "upperLimit": "185.0"}, {"groupId": "BG002", "value": "125.8", "lowerLimit": "72.0", "upperLimit": "364.0"}]}]}]}, {"title": "Serum creatinine", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.1", "lowerLimit": "0.6", "upperLimit": "2.3"}, {"groupId": "BG001", "value": "1.2", "lowerLimit": "0.6", "upperLimit": "1.7"}, {"groupId": "BG002", "value": "1.1", "lowerLimit": "0.6", "upperLimit": "2.3"}]}]}]}, {"title": "Alanine aminotransferase, U/L", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "U/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19.9", "lowerLimit": "10.0", "upperLimit": "39.0"}, {"groupId": "BG001", "value": "27.3", "lowerLimit": "16.0", "upperLimit": "40.0"}, {"groupId": "BG002", "value": "22.4", "lowerLimit": "10.0", "upperLimit": "40.0"}]}]}]}, {"title": "Body temperature", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "degrees Celsius", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37", "lowerLimit": "36", "upperLimit": "37"}, {"groupId": "BG001", "value": "36", "lowerLimit": "36", "upperLimit": "37"}, {"groupId": "BG002", "value": "37", "lowerLimit": "36", "upperLimit": "37"}]}]}]}, {"title": "White blood count", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "cells x 1000/uL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.8", "lowerLimit": "3.9", "upperLimit": "10.6"}, {"groupId": "BG001", "value": "6.4", "lowerLimit": "4.1", "upperLimit": "8.5"}, {"groupId": "BG002", "value": "6.7", "lowerLimit": "3.9", "upperLimit": "10.6"}]}]}]}, {"title": "Hematocrit", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41", "lowerLimit": "32", "upperLimit": "46"}, {"groupId": "BG001", "value": "42", "lowerLimit": "34", "upperLimit": "46"}, {"groupId": "BG002", "value": "41", "lowerLimit": "32", "upperLimit": "46"}]}]}]}, {"title": "Hemoglobin", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13.5", "lowerLimit": "10.4", "upperLimit": "15.9"}, {"groupId": "BG001", "value": "13.8", "lowerLimit": "11.5", "upperLimit": "15.9"}, {"groupId": "BG002", "value": "13.6", "lowerLimit": "10.4", "upperLimit": "15.9"}]}]}]}, {"title": "Platelet count, thousand/uL", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "cells x 1000/uL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "194", "lowerLimit": "113", "upperLimit": "327"}, {"groupId": "BG001", "value": "194", "lowerLimit": "144", "upperLimit": "263"}, {"groupId": "BG002", "value": "194", "lowerLimit": "113", "upperLimit": "327"}]}]}]}, {"title": "Aspartate aminotransferase", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "U/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19.2", "lowerLimit": "13.0", "upperLimit": "34.0"}, {"groupId": "BG001", "value": "24.9", "lowerLimit": "18.0", "upperLimit": "42.0"}, {"groupId": "BG002", "value": "21.1", "lowerLimit": "13.0", "upperLimit": "42.0"}]}]}]}, {"title": "Insulin resistance (homeostasis model assessment)", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "units", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.0", "lowerLimit": "0.6", "upperLimit": "41.3"}, {"groupId": "BG001", "value": "4.4", "lowerLimit": "0.7", "upperLimit": "13.6"}, {"groupId": "BG002", "value": "6.1", "lowerLimit": "0.6", "upperLimit": "41.3"}]}]}]}, {"title": "Estimated glomerular filtration rate", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "mL/min/1.73_m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "71", "lowerLimit": "31", "upperLimit": "123"}, {"groupId": "BG001", "value": "67", "lowerLimit": "30", "upperLimit": "109"}, {"groupId": "BG002", "value": "70", "lowerLimit": "30", "upperLimit": "123"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)", "description": "Adverse Events", "populationDescription": "Total Adverse Events, per participant", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "events/participant", "timeFrame": "up to 12 weeks", "groups": [{"id": "OG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.1", "lowerLimit": "0.0", "upperLimit": "9.0"}, {"groupId": "OG001", "value": "3.2", "lowerLimit": "1.0", "upperLimit": "7.0"}]}]}]}, {"type": "SECONDARY", "title": "On-Trial Change in Whole Blood NAD+ Levels", "description": "Between-group comparison of On-Trial Change in Whole Blood NAD+ Levels", "populationDescription": "Post enrollment, one of the study participants randomized to NR withdraw before the study drug was dispensed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "uM", "timeFrame": "Week 12-Week 0", "groups": [{"id": "OG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.0", "spread": "3.2"}, {"groupId": "OG001", "value": "-0.3", "spread": "0.6"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "The updated p-value is calculated and not a threshold for statistical significance.", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "30.2", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.3"}]}, {"type": "SECONDARY", "title": "Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment", "description": "Incidence of On-Trial Abnormal Laboratory Values and/or Adverse Events that Are Related to Treatment", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "16 weeks", "groups": [{"id": "OG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.05", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "0", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0"}]}, {"type": "SECONDARY", "title": "Effect of NR on Change in Mitochondrial Function (Maximal Oxygen Consumption Rate)", "description": "Mitochondrial Respiration in Isolated Peripheral Blood Mononuclear Cells by the Seahorse (R) Assay", "populationDescription": "One study subject randomized to NR withdrew post enrollment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/min/1,000,000 cells", "timeFrame": "Week 12 - Week 0", "groups": [{"id": "OG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21", "spread": "42"}, {"groupId": "OG001", "value": "2", "spread": "23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.05", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "19", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "48"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Exploratory Endpoint: Effect of NR on Functional Capacity", "description": "Change in Six Minute Walk Distance", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "meters", "timeFrame": "Week 12 - Week 0", "groups": [{"id": "OG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6", "spread": "8"}, {"groupId": "OG001", "value": "1", "spread": "15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.05", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "5", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "17"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Exploratory Endpoint: Effect of NR on Change in Left Ventricular Systolic Function", "description": "Change in Left Ventricular Ejection Fraction by 3D-Transthoracic Echocardiography", "populationDescription": "One study subject randomized to NR withdrew post-enrollment. We were unable to obtain the LVEF for one of the enrolled patient randomized to NR.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of ejection fraction", "timeFrame": "Week 12 - Week 0", "groups": [{"id": "OG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "2.2"}, {"groupId": "OG001", "value": "0.3", "spread": "2.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.05", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "0.3", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.1"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Exploratory Endpoint: Effect of NR on Left Ventricular Diastolic Function", "description": "Tissue Doppler Imaging, e'", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm/sec", "timeFrame": "Week 12 - Week 0", "groups": [{"id": "OG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule"}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.37", "spread": "0.54"}, {"groupId": "OG001", "value": "-0.44", "spread": "0.39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.05", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "0.81", "ciNumSides": "TWO_SIDED", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.66"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "16 weeks", "eventGroups": [{"id": "EG000", "title": "Nicotinamide Riboside", "description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nnicotinamide riboside: nicotinamide riboside capsule", "deathsNumAffected": 0, "deathsNumAtRisk": 20, "seriousNumAffected": 1, "seriousNumAtRisk": 20, "otherNumAffected": 19, "otherNumAtRisk": 20}, {"id": "EG001", "title": "Placebo", "description": "Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.\n\nPlacebo: matching placebo capsule", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 2, "seriousNumAtRisk": 10, "otherNumAffected": 9, "otherNumAtRisk": 10}], "seriousEvents": [{"term": "Myalgia, severe", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 10}]}, {"term": "Acute pulmonary edema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Heart failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}], "otherEvents": [{"term": "Nervous system disorders", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 6, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 10}]}, {"term": "Infections and infestations", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 6, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 10}]}, {"term": "Renal and urinary disorders", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Musculoskeletal and connective tissue disorders", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "General disorders and administration site conditions", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 9, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 10}]}, {"term": "Gastrointestinal disorders", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 10}]}, {"term": "Respiratory, thoracic and mediastinal disorders", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 8, "numAffected": 3, "numAtRisk": 10}]}, {"term": "Skin and subcutaneous tissue disorders", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Metabolism and nutrition disorders", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}, {"term": "Cardiac disorders", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Kevin O'Brien, Study PI", "organization": "University of Washington", "email": "cardiac@uw.edu", "phone": "206-529-7802"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-01-29", "uploadDate": "2022-10-26T17:10", "filename": "Prot_002.pdf", "size": 315860}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-09-27", "uploadDate": "2022-09-27T16:53", "filename": "SAP_003.pdf", "size": 63410}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000054143", "term": "Heart Failure, Systolic"}, {"id": "D000054160", "term": "Systolic Murmurs"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006337", "term": "Heart Murmurs"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27579", "name": "Heart Failure, Systolic", "asFound": "Heart Failure, Systolic", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "asFound": "Systolic", "relevance": "HIGH"}, {"id": "M9425", "name": "Heart Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000009536", "term": "Niacinamide"}, {"id": "D000009525", "term": "Niacin"}, {"id": "D000009539", "term": "Nicotinic Acids"}], "ancestors": [{"id": "D000014803", "term": "Vitamin B Complex"}, {"id": "D000014815", "term": "Vitamins"}, {"id": "D000018977", "term": "Micronutrients"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}], "browseLeaves": [{"id": "M12476", "name": "Niacinamide", "asFound": "Optical Coherence Tomography", "relevance": "HIGH"}, {"id": "M12465", "name": "Niacin", "asFound": "Optical Coherence Tomography", "relevance": "HIGH"}, {"id": "M12479", "name": "Nicotinic Acids", "asFound": "Optical Coherence Tomography", "relevance": "HIGH"}, {"id": "M17558", "name": "Vitamins", "relevance": "LOW"}, {"id": "M17546", "name": "Vitamin B Complex", "relevance": "LOW"}, {"id": "M8618", "name": "Folic Acid", "relevance": "LOW"}, {"id": "M21009", "name": "Micronutrients", "relevance": "LOW"}, {"id": "M16885", "name": "Trace Elements", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "T455", "name": "Nicotinamide", "asFound": "Optical Coherence Tomography", "relevance": "HIGH"}, {"id": "T453", "name": "Niacin", "asFound": "Optical Coherence Tomography", "relevance": "HIGH"}, {"id": "T454", "name": "Niacinamide", "asFound": "Optical Coherence Tomography", "relevance": "HIGH"}, {"id": "T456", "name": "Nicotinic Acid", "asFound": "Optical Coherence Tomography", "relevance": "HIGH"}, {"id": "T471", "name": "Vitamin B3", "asFound": "Optical Coherence Tomography", "relevance": "HIGH"}, {"id": "T446", "name": "Folic Acid", "relevance": "LOW"}, {"id": "T448", "name": "Folate", "relevance": "LOW"}, {"id": "T475", "name": "Vitamin B9", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "Hemat", "name": "Hematinics"}, {"abbrev": "Vi", "name": "Vitamins"}]}}, "hasResults": true}